Research Paper Volume 13, Issue 15 pp 19908—19919

A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p/miR-17-3p-TIMP3 axis

circSMARCA5 sponged miR-181b-5p/miR-17-3p to regulate TIMP3. (A) qRT-PCR for the pulled-down circSMARCA5. (B) qRT-PCR for circSMARCA5 enrichment in DU145 cell lysates. (C) qRT-PCR for miR-181b-5p and miR-17-3p. (D) Luciferase activities in the cells with indicated treatments. (E) Correlation between circSMARCA5 expression and miR-181b-5p, or miR-17-3p, in prostate tumor tissues. (F) Luciferase activities in the cells with indicated treatments. (G) Western blot for TIMP3 expression after overexpression or downregulation of miR-17-3p. (H) Western blot for the expression of TIMP3 after circSMARCA5 overexpression, or downregulation. *, **, *** represent p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, respectively. Assays were performed at least three times.

Figure 5. circSMARCA5 sponged miR-181b-5p/miR-17-3p to regulate TIMP3. (A) qRT-PCR for the pulled-down circSMARCA5. (B) qRT-PCR for circSMARCA5 enrichment in DU145 cell lysates. (C) qRT-PCR for miR-181b-5p and miR-17-3p. (D) Luciferase activities in the cells with indicated treatments. (E) Correlation between circSMARCA5 expression and miR-181b-5p, or miR-17-3p, in prostate tumor tissues. (F) Luciferase activities in the cells with indicated treatments. (G) Western blot for TIMP3 expression after overexpression or downregulation of miR-17-3p. (H) Western blot for the expression of TIMP3 after circSMARCA5 overexpression, or downregulation. *, **, *** represent p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, respectively. Assays were performed at least three times.